Blog
RSS FeedPosted by Michael Wonder on 18 Dec 2018
Cipher Pharmaceuticals announces A-101 40% topical solution accepted for review by Health Canada
18 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for A-101 40% topical solution ("A-101 40%") ...
Posted by Michael Wonder on 18 Dec 2018
Cipher Pharmaceuticals announces plecanatide accepted for review by Health Canada
17 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for plecanatide for irritable bowel syndrome with ...
Posted by Michael Wonder on 18 Dec 2018
Emergent BioSolutions receives Health Canada approval of BioThrax (anthrax vaccine adsorbed)
17 December 2018 - Emergent BioSolutions today announced that Health Canada has approved the company’s new drug submission for its anthrax ...
Posted by Michael Wonder on 17 Dec 2018
Health Canada approves Darzalex (daratumumab) for newly diagnosed patients with multiple myeloma who are transplant ineligible
17 December 2018 - Darzalex combination therapy significantly reduced the risk of disease progression or death compared to a preferred regimen ...
Posted by Michael Wonder on 14 Dec 2018
Health Canada grants market authorisation for Orkambi (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old with most common form of the disease
13 December 2018 - Orkambi is the first medicine in Canada to treat the underlying cause of cystic fibrosis in young ...
Posted by Michael Wonder on 09 Dec 2018
Zaxine (rifaximin) - now indicated in Canada for patients with irritable bowel syndrome with diarrhoea
6 December 2018 - Lupin Pharma Canada is pleased to announce the approval from Health Canada for Zaxine 550 mg (rifaximin) ...
Posted by Michael Wonder on 06 Dec 2018
Ultragenyx and Kyowa Kirin announce Health Canada approval of Crysvita (burosumab injection) for the treatment of X–linked hypophosphataemia in adults and children
6 December 2018 - First approved treatment for XLH in Canada that targets the underlying cause of this rare, hereditary, lifelong ...
Posted by Michael Wonder on 06 Dec 2018
Alberta boy with thyroid cancer runs, plays after taking U.S. approved drug
5 December 2018 - Health Canada is considering approving the oral treatment, larotrectinib. ...
Posted by Michael Wonder on 28 Nov 2018
Alimera Sciences announces Canadian regulatory approval for Iluvien
26 November 2018 - Alimera Sciences today announced that Health Canada has approved Iluvien for the treatment of diabetic macular oedema. ...
Posted by Michael Wonder on 28 Nov 2018
Health Canada has now authorised Adynovate [anti-haemophilic factor (recombinant), PEGylated] in paediatrics for treatment of children under 12 with haemophilia A
26 November 2018 - Canadian children now have access to Adynovate, which offers a twice-weekly prophylaxis dosing schedule and on-demand control ...
Posted by Michael Wonder on 25 Nov 2018
Canada has found the key to lowering drug prices, but it won't be used any time soon
24 November 2018 - Health Canada has quietly delayed implementation date for controversial drug rules. ...
Posted by Michael Wonder on 24 Nov 2018
Indivior announces Health Canada approval of Sublocade (buprenorphine extended release) injection for patients with moderate to severe opioid use disorder
23 November 2018 - Sublocade is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of ...
Posted by Michael Wonder on 15 Nov 2018
Inclusion of data on treatment discontinuation in the Tasigna product monograph approved by Health Canada for CML patients who achieve a sustained molecular response
13 November 2018 - Approval is based on two studies showing more than half of patients remained in remission after stopping ...
Posted by Michael Wonder on 12 Nov 2018
Oversight gap at private infusion clinics poses health risk, Ontario documents say
12 November 2018 - The lack of formal oversight at private clinics where medications are administered intravenously could pose risks ...
Posted by Michael Wonder on 02 Nov 2018
Servier receives Health Canada approval of Folotyn for the treatment of relapsed or refractory peripheral T-cell lymphoma
1 November 2018 - Servier Canada announced that Health Canada granted a Notice of Compliance with conditions for Folotyn (pralatrexate) for ...